Loading...
Stem Holdings, Inc.
STEM.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.31
CA$0.00(0.00%)

Over the last four quarters, Stem Holdings, Inc. achieved steady financial progress, growing revenue from $4.06M in Q1 2023 to -$11.78M in Q4 2023. Gross profit stayed firm with margins at 100% in Q4 2023 versus 1% in Q1 2023. Operating income totaled $2.62M in Q4 2023, maintaining a -22% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $2.33M. Net income dropped to -$11.61M, with EPS at $0.26. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan